INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 21 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $520,115 | -49.9% | 521,000 | -50.0% | 0.00% | – |
| Q4 2022 | $1,038,120 | +105.2% | 1,042,000 | +100.0% | 0.00% | – |
| Q3 2022 | $506,000 | -0.6% | 521,000 | 0.0% | 0.00% | – |
| Q2 2022 | $509,000 | +6.0% | 521,000 | 0.0% | 0.00% | – |
| Q1 2022 | $480,000 | -67.1% | 521,000 | -65.7% | 0.00% | – |
| Q4 2021 | $1,457,000 | +5.9% | 1,521,000 | 0.0% | 0.00% | – |
| Q3 2021 | $1,376,000 | -85.9% | 1,521,000 | -85.7% | 0.00% | -100.0% |
| Q2 2021 | $9,766,000 | +10.2% | 10,663,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $8,864,000 | +7.0% | 10,663,000 | +3.9% | 0.00% | 0.0% |
| Q4 2020 | $8,281,000 | +10.0% | 10,263,000 | +10.8% | 0.00% | 0.0% |
| Q3 2020 | $7,531,000 | -13.5% | 9,263,000 | -18.5% | 0.00% | 0.0% |
| Q2 2020 | $8,705,000 | -20.9% | 11,363,000 | -15.6% | 0.00% | 0.0% |
| Q1 2020 | $11,004,000 | -22.4% | 13,463,000 | -2.8% | 0.00% | 0.0% |
| Q4 2019 | $14,189,000 | +19.6% | 13,855,000 | +1.1% | 0.00% | 0.0% |
| Q3 2019 | $11,860,000 | -3.4% | 13,700,000 | +1.1% | 0.00% | 0.0% |
| Q2 2019 | $12,275,000 | -6.7% | 13,550,000 | +2.7% | 0.00% | 0.0% |
| Q1 2019 | $13,151,000 | +1.6% | 13,200,000 | -4.7% | 0.00% | 0.0% |
| Q4 2018 | $12,943,000 | -12.5% | 13,850,000 | -5.0% | 0.00% | 0.0% |
| Q3 2018 | $14,793,000 | +4.5% | 14,575,000 | -8.0% | 0.00% | 0.0% |
| Q2 2018 | $14,156,000 | +17.9% | 15,850,000 | +7.3% | 0.00% | 0.0% |
| Q1 2018 | $12,003,000 | +4.7% | 14,775,000 | +5.3% | 0.00% | 0.0% |
| Q4 2017 | $11,467,000 | +19.9% | 14,025,000 | +15.2% | 0.00% | 0.0% |
| Q3 2017 | $9,567,000 | – | 12,175,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|